Showing 8021-8030 of 8862 results for "".
- L'Oréal Buys CeraVe, AcneFree and AMBI from Valeanthttps://practicaldermatology.com/news/loral-buys-cerave-acnefree-and-ambi-from-valeant/2458322/Valeant Pharmaceuticals International, Inc. is selling CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion in cash. The transaction is expected to close in the first quarter of
- Smart Hairbrush and Overachieving Mirrors Make Waves at CES 2017https://practicaldermatology.com/news/smart-hairbrush-and-overachieving-mirrors-make-waves-at-ces-2017/2458328/Beauty is getting a whole lot smarter, and more and more companies are getting in on the game. These are among the main takeaways from the BeautyTech Summit at the annual Consumer Electronics Show (CES), taking place in Las Vegas from Jan. 5-8, 2017. This is the be-all, end-all trade show
- New Compound May Block Spread of Melanoma, Treat Sclerodermahttps://practicaldermatology.com/news/new-compound-may-block-spread-of-melanoma-treat-scleroderma/2458329/A chemical compound, and potential new drug, may reduce the spread of melanoma cells by up to 90 percent, report researchers from Michigan State University in East Lansing. The man-made, small-molecule drug compound goes after a gene’s ability to produce RNA molecules and certain pr
- Study Examines Diversity in Dermatologic Clinical Trialshttps://practicaldermatology.com/news/study-examines-diversity-in-dermatologic-clinical-trials/2458332/Dermatologic clinical trials within the United States reflect the growing diversity of the US population, but reporting of both sex and racial/ethnic diversity of research cohorts is still lacking, especially among studies conducted outside of the United States, according to a new report publishe
- Melanoma Incidence, Mortality On The Risehttps://practicaldermatology.com/news/melanoma-incidence-mortality-on-the-rise/2458339/Melanoma incidence and mortality is on the rise, according to a research letter published online by JAMA Dermatology. An estimated 76,380 Americans will be diagnosed with melanoma in 2016, and
- Oculus Innovative Sciences' SebuDerm Gel Availablehttps://practicaldermatology.com/news/fda-clears-oculus-innovative-sciences-sebuderm-gel/2458340/Oculus Innovative Sciences, Inc.’s Microcyn-based SebuDerm Gel is available in the US. As a prescription product, SebuDerm Gel is intended to manage and relieve the burning, itching, erythema, scaling, and pain experienced with seborrhea and seborrheic dermatitis. The gel, which
- With LifeCell Acquisition, Allergan Enters Regenerative Medicine Realmhttps://practicaldermatology.com/news/with-lifecell-acquisition-allergan-enters-regenerative-medicine-realm/2458341/Allergan plc has acquired the regenerative medicine company LifeCell for $2.9 billion in cash, subject to customary adjustments, Allergan reports. This acquisition combines LifeCell's products ALLODERM® and STRATTICETM tissue matrices commonly use
- Sandoz Acquires AmLactin Brandhttps://practicaldermatology.com/news/sandoz-acquires-amlactin-brand/2458342/Sandoz today announced that it has acquired the AmLactin® family of skin care brands from Minnesota-based pharmaceutical company Upsher-Smith Laboratories, Inc.
- FDA Approved Eucrisa (Crisaborole) for ADhttps://practicaldermatology.com/news/fda-approved-eucrisa-crisaborole-for-ad/2458344/The U.S. Food and Drug Administration approved Eucrisa (crisaborole) ointment to treat mild-to-moderate eczema in patients two years of age and older. Eucrisa, applied topically twice daily, is a phosphodiesterase 4 (PDE-4) i
- Valeant Appoints William D. Humphries As EVP, Dermatologyhttps://practicaldermatology.com/news/valeant-appoints-william-d-humphries-as-evp-dermatology/2458348/Valeant Pharmaceuticals International, Inc. appointed William D. Humphries as Executive Vice President, Dermatology, effective January 2, 2017. Mr. Humphries will join Valeant's Executive Committee, reporting directly to